Skip to content

Study · Case report or series · n = 1 · 2025

1 result

Weighing the Risks: Small Bowel Obstruction Associated With Semaglutide Use in the Postoperative Abdomen.

Nagib N, Avila D, Partyka J, Kamyab A

Cureus23 Jul 2025Cited by 2 (Europe PMC)

PMID40861748 (opens in a new tab)PMCIDPMC12372858 (opens in a new tab)DOI10.7759/cureus.88589 (opens in a new tab)PepBankPUB-40861748
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist increasingly prescribed for weight loss, is generally well tolerated but may have underrecognized gastrointestinal complications. We present the case of a 59-year-old woman with an extensive abdominal surgical history who developed small bowel obstruction (SBO) shortly after semaglutide administration. Given semaglutide's effects on gastric motility and its rising use, this case highlights the importance of caution when prescribing GLP-1 agonists to patients with a history of intra-abdominal surgeries and intra-abdominal adhesions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 59-year-old woman with an extensive abdominal surgical history, small bowel obstruction developed shortly after semaglutide administration.

    In plain wordsA 59-year-old woman with past abdominal surgery developed a bowel blockage soon after starting semaglutide; one case cannot show semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicableSmall bowel obstruction
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present the case of a 59-year-old woman with an extensive abdominal surgical history who developed small bowel obstruction (SBO) shortly after semaglutide administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.